Immunitybio公布第二季度亏损后股价下跌

路透中文
Aug 04
BUZZ-Immunitybio公布第二季度亏损后股价下跌

8月4日 - ** Immunitybio Inc(IBRX.O)股价下跌3%,报6.94美元

** 这家生物科技公司公布第二季度每股亏损22美分,而市场预期为每股亏损9美分——LSEG数据

** 上半年净亏损从2025年的2.222亿美元扩大至2026年的8.632亿美元

** 营收较去年同期增长93.9%至5124万美元,高于4970万美元的预期

** IBRX将营收增长归因于其膀胱癌药物Anktiva 在美国泌尿科医生中的 持续采用以及强劲的市场准入

** 公司表示,预计未来12个月内将达成多项监管和临床里程碑

** 计入本交易日涨幅在内,IBRX今年以来累计上涨约260%,表现远超纳斯达克 .IXIC 指数12.8%的涨幅

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10